Zobrazeno 1 - 10
of 37
pro vyhledávání: '"MUKUND S. DIDOLKAR"'
Autor:
William F. Regine, MD, Kathryn Winter, MS, Ross A. Abrams, MD, Howard Safran, MD, Ivan L. Kessel, MD, Yuhchyau Chen, MD, PhD, James A. Fugazzi, MD, Eric D. Donnelly, MD, Thomas A. DiPetrillo, MD, Samir Narayan, MD, John P. Plastaras, MD, Rakesh Gaur, MD, Guila Delouya, MD, John H. Suh, MD, Joshua E. Meyer, MD, Michael G. Haddock, MD, Mukund S. Didolkar, MD, Gilbert D.A. Padula, MD, David Johnson, MD, John P. Hoffman, MD, Christopher H. Crane, MD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 2, Pp 154-162 (2018)
Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predict
Externí odkaz:
https://doaj.org/article/7807a6dd9b14475d9809d5afcb59b0df
Autor:
Kathryn Winter, Yuhchyau Chen, Rakesh Gaur, Samir Narayan, James A. Fugazzi, John P. Plastaras, Christopher H. Crane, Joshua E. Meyer, John P. Hoffman, Ross A. Abrams, Guila Delouya, Eric D. Donnelly, Mukund S. Didolkar, William F. Regine, John H. Suh, Ivan L. Kessel, David H. Johnson, Thomas A. DiPetrillo, Gilbert D.A. Padula, Michael G. Haddock, Howard Safran
Publikováno v:
Advances in Radiation Oncology
Advances in Radiation Oncology, Vol 3, Iss 2, Pp 154-162 (2018)
Advances in Radiation Oncology, Vol 3, Iss 2, Pp 154-162 (2018)
Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce6ca568378f762b0319551c6fdb8dc1
http://europepmc.org/articles/PMC6000159
http://europepmc.org/articles/PMC6000159
Autor:
Mark J. Brenner, Mukund S. Didolkar, Elizabeth Stanwyck, Nagaraj K. Neerchal, Nicole Olexa, Kyo U. Chu, Airong Yu, Stuart Rabinowitz, Cardella W. Coleman
Publikováno v:
Journal of Gastrointestinal Surgery. 14:1547-1559
Locally advanced unresectable pancreatic adenocarcinoma is characterized by poor survival despite chemotherapy and conventional radiation therapy (RT). Recent advances in real-time image-guided stereotactic radiosurgery (SRS) have made it possible to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a52d909af5a17dec75646e0fd7daa16
https://doi.org/10.1007/s11605-010-1323-7
https://doi.org/10.1007/s11605-010-1323-7
Autor:
Vernon K. Sondak, Sarah A. Taylor, John R. Eckardt, Lawrence E. Flaherty, Mukund S. Didolkar, Robert P. Whitehead, Joseph M. Unger, Wolfram E. Samlowski
Publikováno v:
Investigational New Drugs. 19:239-243
Malignant melanoma is increasing in frequency at a rapid rate in the United States. Metastatic disease is chemoresistant with DTIC considered the most active single agent. CI-980 is a synthetic mitotic inhibitor that blocks the assembly of tubulin an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddf5ed2e281a1b8bde1d5a31297ace4
https://doi.org/10.1023/a:1010624702340
https://doi.org/10.1023/a:1010624702340
Publikováno v:
Endocrine pathology. 24(3)
Angiosarcoma is a rare and aggressive tumor of the thyroid gland, mainly seen in the Alpine regions. We present such a case with literature review. We present the case of a 60-year-old man with cough, dyspnea, and hemoptysis along with slow increase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::534f23433478f35666f4d1a33c834515
https://pubmed.ncbi.nlm.nih.gov/23794134
https://pubmed.ncbi.nlm.nih.gov/23794134
Autor:
J. Lawrence Fitzpatrick, Loren A. Zech, Mukund S. Didolkar, Gerald S. Johnston, Barbara S. Buda, Andre J. Jackson, Lawrence J. Lesko
Publikováno v:
Journal of Surgical Oncology. 63:148-158
Background : The pharmacokinetics of dacarbazine (DTIC), which has been shown to be an effective therapeutic agent against metastatic melanoma, has not been extensively studied. However, to improve the clinical use of the drug, more information on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad3fc0402a8015ffd27385e6b0707f96
https://doi.org/10.1002/(sici)1096-9098(199611)63:3<148::aid-jso4>3.0.co
https://doi.org/10.1002/(sici)1096-9098(199611)63:3<148::aid-jso4>3.0.co
Autor:
Gregory P. Midis, Adine Feuer, Stewart A. Bergman, Mukund S. Didolkar, Alan T. Lefor, E. George Elias
Publikováno v:
Journal of Surgical Oncology. 50:22-26
Internal mandibular fixation after resection of advanced oral cavity carcinoma with mandibulectomy has a significant complication rate. We placed the Joe Hall Morris (JHM) external mandibular appliance in 29 patients undergoing mandibulectomy for adv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746e0e563449aeb7e9e1d97493e67148
https://doi.org/10.1002/jso.2930500109
https://doi.org/10.1002/jso.2930500109
Publikováno v:
The American Journal of Surgery. 162:231-235
Twenty-eight patients with inflammatory carcinoma of the breast were managed initially by induction chemotherapy consisting of 3 courses of a combination of cyclophosphamide, doxorubicin hydrochloride, and 5-fluorouracil. Twenty-two showed a partial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb6d8d7a672e67e88dcfd6cca8e1b35
https://doi.org/10.1016/0002-9610(91)90076-p
https://doi.org/10.1016/0002-9610(91)90076-p
Autor:
Wayne J. Ivusich, Mukund S. Didolkar, James H. Resau, Neil Caporaso, Karen L. Fisher, Laureen A. Green-Gallo, Robert G. Slawson, Daina M. Buivys, E. George Elias
Publikováno v:
Cancer. 68:206-210
The genetically determined ability to metabolize the antihypertensive drug debrisoquine has been proposed as a genetic risk factor for primary carcinomas of the lung. To test this hypothesis, the metabolism of the drug was evaluated in a case control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59e6c8228a0bc293524a35f68b452978
https://doi.org/10.1002/1097-0142(19910701)68:1<206::aid-cncr2820680138>3.0.co
https://doi.org/10.1002/1097-0142(19910701)68:1<206::aid-cncr2820680138>3.0.co
Autor:
John P. Plastaras, James A. Fugazzi, David B. F. Johnson, Gilbert D. A. Padula, Rakesh Gaur, Yuhchyau Chen, Ivan L. Kessel, Samir Narayan, Eric D. Donnelly, Mukund S. Didolkar, Thomas A. DiPetrillo, Michael G. Haddock, Christopher H. Crane, Joshua E. Meyer, Kathryn Winter, John H. Suh, William F. Regine, Guila Delouya, John P. Hoffman
Publikováno v:
Journal of Clinical Oncology. 33:347-347
347 Background: 9,704 was the first phase 3 pancreatic cancer trial to validate the prognostic value of postresection CA19-9 for overall survival (OS), with values > 90/180 associated with worse OS. All pts received adjuvant gemcitabine or 5-FU and c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53fa3224007bcbf3af4fd69ec153df2d
https://doi.org/10.1200/jco.2015.33.3_suppl.347
https://doi.org/10.1200/jco.2015.33.3_suppl.347